Safety and immunogenicity of an attenuated Chinese pseudorabies variant by dual deletion of TK&gE genes

Jichun Wang1,2, Zengcai Song3, Aimin Ge4, Rongli Guo2,5, Yongfeng Qiao1,2, Mengwei Xu1,2, Zhisheng Wang1,2, Yamei Liu1,2, Yating Zheng1,2, Hongjie Fan3 and Jibo Hou1,2*

Abstract

Background: Since the outbreak of a new emerging virulent pseudorabies virus mutant in Chinese pig herds, intensive research has been focused on the construction of novel gene deletion vaccine based on the variant virulent viruses. An ideal vaccine candidate is expected to have a balanced safety and immunogenicity.

Results: From the infectious clone of PRV AH02LA strain, a TK deletion mutant was generated through two-step Red mutagenesis. After homologous recombination with a transfer vector, a TK&gE dual deficient mutant PRV (PRVΔTK&gE-AH02) was generated, and its structure verified by PCR, RFLP and sequencing. Growth kinetics test showed that PRVΔTK&gE-AH02 reached a titer of 10^{7.5} TCID_{50}/mL on ST cells. The PRVΔTK&gE-AH02 at a dose of 10^{6.0} TCID_{50}/animal was not virulent in mice or 1-day-old piglets with maternal PRV antibodies. No clinical signs or virus shedding were detected in 28~35-day-old piglets without maternal PRV antibodies. Although it caused one death of four 1-day-old piglets without maternal PRV antibodies. In the efficiency test of PRVΔTK&gE-AH02, all four 28~35-day-old piglets without PRV antibody in the challenge control showed typical clinical symptoms and virus shedding, and two died at 4~5 days post challenge. All piglets in 10^{6.0}, 10^{4.0} and 10^{3.0} TCID_{50}/dose PRVΔTK&gE-AH02 groups provided complete protection against challenge at only 7 days post intramuscular vaccination. More importantly, PRVΔTK&gE-AH02 stopped virus shedding in these piglets. In contrast, all four piglets in PRV Bartha K61 vaccine group developed high body temperature (≥40.5 °C) and viral shedding, despite they had mild or even no clinical symptoms.

Conclusions: The constructed TK&gE dual deletion mutant PRVΔTK&gE-AH02 can reach high titers on ST cells. The live vaccine of PRVΔTK&gE-AH02 is highly safe, and can not only provide clinical protection but also stops virus shedding. This study suggests that PRVΔTK&gE-AH02 might work as a promising vaccine candidate to combat the PRV variant emerging in Chinese herds since 2011.

Keywords: Pseudorabies virus emerging variant, TK&gE dual deletion, Attenuation, Live vaccine, Safety, Immunogenicity

* Correspondence: houjibocvv@163.com
1National Research Center of Engineering and Technology for Veterinary Biologicals/Institute of Veterinary Immunology & Engineering, Jiangsu Academy of Agricultural Sciences, Nanjing 210014, Jiangsu, China
2Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, China
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Since 2011, a new emerging pseudorabies virus (PRV) variant has swept many Chinese pig herds, leading to infection or disease of variable severity [1–4]. Several studies have shown that PRV Bartha K61 vaccine can only provide clinical protection against the new PRV mutants, but fail to stop virus shedding in piglets post challenge [5]. It is therefore urgent to develop a more efficacious vaccine in order to eradicate the virulent PRV variant. Since successful eradication of pseudorabies in many nations have been achieved via the application of gene deletion DIVA (differentiating infected from vaccinated animals) vaccines [6–9], gene deletion mutants of the emerging PRV may be promising vaccine candidates for infection control and eradication [10].

Expectedly, PRV glycoprotein E (gE) gene is one target of deletion for differentiation purpose [11, 12]. For further attenuation, thymidine kinase (TK), glycoprotein I (gI) and/or glycoprotein G (gG) genes were also chosen as targets for deletion to generate gE&gI, TK&gE, TK&gE&gI or TK&gG deletion mutants [6, 13]. Several mutants of gE, gE&gI or gE&gI&TK deletion from the new variant have been generated and evaluated for safety and immunogenicity [11, 12, 14–19]. However, the safety and/or immunogenicity of these mutants is far from being satisfactory. TK is associated with virulence and reactivation from latent infection of PRV, and therefore the deletion of TK leads to attenuation of virulent PRV [20, 21]. As known, gE can form complexes with gI to obtain neuro-tropism and reactivation. It is proposed that gI will lose this function without gE, while immune stimulation by gI will be reserved. A TK&gE dual deletion mutant of the wild-type PRV TNL strain, which was isolated from a commercial pig farm in southern Taiwan in 1976, has been generated and proposed potential vaccine candidate with safety, efficacy and DIVA capability [22]. To our knowledge, no TK&gE deletion mutant from the new emerging Chinese variant has been reported so far.

Therefore, in this study, a TK&gE dual deletion mutant was constructed using a bacterial artificial chromosome clone of the emerging PRV AH02LA strain. Safety and immunogenicity of this mutant was evaluated in regard to its potency as a vaccine candidate for the control or eradication of the new emerging pseudorabies virus in Chinese pig herds.

Methods

Cells and viruses
Swine testicular (ST) cells (CVCC:CL27, from China Veterinary Culture Collection Center), and primary or secondary chicken embryo cells (CECs) made from 10 days SPF chicken embryo (from Beijing Merial Vital Laboratory Animal Technology Co., Ltd.) were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco) supplemented with 2–10% newborn calf serum (NCS, Gibco), 100 U/mL penicillin and 100 μg/mL streptomycin at 37 °C, 5% CO₂ atmosphere. The PRV AH02LA strain was isolated and identified in our lab (CGMCC No. 10891) [23]. The gE deletion mutant (LA-A⁰) from AH02LA strain was constructed in our lab as reported previously [23]. The PRV Bartha K61 strain was kindly provided by Professor Ping Jiang at the Nanjing Agricultural University, China. Virus cultures and stocks were prepared using CECs or ST cells and were frozen in aliquots at -70 °C after three round of freeze-thawing (~70 °C and 37 °C). Virus titers were determined by TCID₅₀ on ST cells following the Reed-Muench method. Viral Deoxyribonucleic acid (DNA) was extracted from infected cells by the sodium dodecyl sulfate (SDS)-proteinase K method. Transfection of plasmid, virus or bacterial artificial chromosome (BAC) DNA were performed using Lipofectamine® 3000 (Invitrogen) following manual of supplier.

Bacterial manipulation
The BAC of PRV AH02LA strain (BACPRV-G), constructed previously in our lab [23], was used for generation of TK&gE deletion mutant. Plasmid and BAC DNAs were prepared with commercial kits (QIAGEN). Restriction fragment length polymorphism (RFLP) analyses of PRV BAC or BAC mutants was conducted using the restriction endonucleases Kpn I (Takara) as described earlier [24]. Electroporation was performed to transform plasmid or BAC DNA as previously described [24].

PCR and sequencing
To conduct En Passant recombination, a pair of primers (PRV ΔTK En pa F/R) for amplification of kanamycin resistance gene was designed with 60 bp homologous sequences (Fig. 1a)(Table 1) [25]. Primers of PRV ΔTK check F/R were used for check of correct insertion of kanamycin resistance gene and correct deletion of TK gene (Table 1). Primers (PRV BAC H1 F and PRV BAC H2 R) were designed from a reference sequence (GenBank:NC_006151.1) to amplify a DNA fragment including upstream and downstream homologous arms, the intact gI gene and part of gE gene(1299 bp to 1735 bp of gE ORF) (Fig. 1d) (Table 1) using isolated PRV LA-A⁰ strain DNA as template. The correct deletion of gE was verified with a pair of primers (PRV ΔgE check F/R) (Table 1). The primers used for sequencing gI gene were prepared as described previously (GeneScript, Nanjing China). [26]

Construction of PRV BAC deletion mutants
The PRV BAC TK deletion mutant was constructed from BACPRV-G following En Passant protocol as described previously (Fig. 1a, b and c) [27]. Briefly, after
digestion with Dpn I, approximately 100 ng of purified DNA fragments amplified with primers of PRV ΔTK En pa F/R was electroporated into BAC<sup>PRV-G</sup> at 1500 V/cm, a resistance and a capacitance of 25F(Precision Pulse, ECM630 BTX). Colonies with resistance to both chloramphenicol(34 μg/mL) and kanamycin(50 μg/mL) were checked through PCR with a pair of primers(PRV ΔTK check F/R) and through RFLP after digestion with <sup>I</sup>Kpn. One correct colony consistent with prediction from reference sequence of PRV ZJ01 strain (GenBank:KM061380.1) was used for the 2nd Red recombination to remove the kanamycin resistance gene (Fig. 1c). Colonies sensitive to kanamycin but resistant to chloramphenicol were double checked for the correct deletion of TK gene through PCR and RFLP as described above.

To generate the TK&gE deletion mutant of PRV AH02LA strain, another homologous recombination was performed to recover the gI gene and the undeleted sequences of gE (Fig. 1d). Briefly, PCR was carried out using primers PRV BAC H1 F and PRV BAC H2 F R (Table 1) and the PRV LA-A<sup>RA</sup> DNA as template. Primary CECs were co-transfected with approximately 1 μg of PRV BAC DNA and 100ng of DNA fragment from the PCR reaction using Lipofectamine<sup>™</sup> 3000 (Invitrogen<sup>™</sup>). Non-fluorescent virus plaques were purified after several round of picking and plating to obtain a homogeneous virus populations. Selected viruses were confirmed for correct deletion of TK gene and gE gene by PCR and sequencing using primers(PRV ΔTK check F/R and PRV ΔgE check F/R) (Table 1), and the recovery of gI gene were checked as described previously [23].
**Multistep growth kinetics**

Multistep growth kinetics of parental AH02LA, gE deletion mutant (LA-A^B strain), and TK&gE dual deletion mutant (PRV ΔTK&gE-AH02) viruses were conducted following the methods as described previously with slight modifications [24]. Briefly, supernatant and cell-associated virus titers were determined before infection and at 6, 12, 24, 36, 48 and 72 h post infection (P.I.) on monolayers (1 × 10^6 cells) of ST cells with a multiplicity of infection (MOI) of 0.01. Viruses from supernatant or released from cells by three freeze-thaw cycles were titrated on fresh ST cells. Three independent experiments were conducted and one-way ANOVA (SPSS software package 17.0, IBM SPSS, Chicago, IL, USA) was employed for statistical analysis.

**Preparation of vaccine**

PRV ΔTK&gE-AH02, PRV LA-A^B and Bartha K61 viruses were propagated on ST cells using a 5 l bioreactor, each virus stock was titrated by TCID_{50} following the Reed-Muench method on ST cells. All vaccines were confirmed to be free of bacteria and fungi following standard method as described in “People’s Republic of China Veterinary Pharmacopoeia, 2015 edition”, and were stored at -70 °C until use.

**Test of vaccine safety of PRV ΔTK&gE-AH02**

Twenty one-day-old PRV gB antibody negative piglets (from Zhengzhuquan Pig Breeding Farm in Pukou district, Nanjing, China), free of porcine reproductive and respiratory syndrome virus (PRRSV), porcine parvovirus (PPV), porcine circovirus 2 (PCV2) and classical swine fever virus (CSFV), were divided into 5 groups. In group A(N) and B(N) piglets were inoculated intranasally (I.N.) with PRV ΔTK&gE-AH02 and PRV LA-A^B respectively with a dose of 10^7.0TCID_{50}, while in group C(N) and D(N) intramuscularly (I.M.) respectively. Group E(N) was inoculated 2 mL PBS as placebo control (Table 2). Clinical signs were monitored daily for 14 days. Serum samples were collected for PRV gB and gE antibodies test at 14 days P.I..

| Groups | Inoculation route | PRV strain tested | ELISA antibodies against PRV gB or gE | Morbidity | Mortality | ELISA antibodies against PRV gB or gE | Morbidity | Mortality |
|--------|------------------|-------------------|---------------------------------------|-----------|-----------|---------------------------------------|-----------|-----------|
| Groups | Inoculation route | PRV strain tested | ELISA antibodies against PRV gB or gE | Morbidity | Mortality | ELISA antibodies against PRV gB or gE | Morbidity | Mortality |
| A(N)   | I.N.             | PRV ΔTK&gE-AH02   | gB+ 0/4                               | 2/4       | 1/4       | gE+ 0/4                               | 3/4       | 0/4       |
| B(N)   | I.M.             | PRV LA-A^B        | 0/4                                   | 4/4       | 1/4       | 0/4                                   | 4/4       | 0/4       |
| C(N)   | I.N.             | PRV ΔTK&gE-AH02   | gB+ 3/3                               | 2/4       | 0/4       | gE+ 3/3                               | 2/4       | 0/4       |
| D(N)   | I.M.             | PRV LA-A^B        | 4/4                                   | 4/4       | 4/4       | 4/4                                   | 4/4       | 4/4       |
| E(N)   | I.N.             | PRV ΔTK&gE-AH02   | 0/4                                   | 0/4       | 0/4       | 0/4                                   | 0/4       | 0/4       |
| A(P)   | I.N.             | PRV ΔTK&gE-AH02   | gB+ 4/4                               | 4/4       | 4/4       | gE+ 4/4                               | 4/4       | 4/4       |
| B(P)   | I.M.             | PRV LA-A^B        | 4/4                                   | 4/4       | 4/4       | 4/4                                   | 4/4       | 4/4       |
| C(P)   | I.N.             | PRV ΔTK&gE-AH02   | 0/4                                   | 0/4       | 0/4       | 0/4                                   | 0/4       | 0/4       |
| D(P)   | I.M.             | PRV LA-A^B        | 0/4                                   | 0/4       | 0/4       | 0/4                                   | 0/4       | 0/4       |
| E(P)   | I.N.             | PRV ΔTK&gE-AH02   | 0/4                                   | 0/4       | 0/4       | 0/4                                   | 0/4       | 0/4       |

I.N. means intranasally, I.M. means intramuscularly, gB+ means antibodies against PRV gB positive, gE+ means antibodies against PRV gE positive, B.I. means before inoculation, P.I. means post inoculation. * indicates the number of piglets positive; ** indicates the number of piglets in the group.
PRRSV, PPV, PCV2 and CSFV, were divided into 5 groups of A(P), B(P), C(P), D(P) and E(P). All piglets were treated and monitored exactly as those PRV gB antibody negative piglets (Table 2).

Safety of PRV mutants in mice (Balb/c mice, from Nanjing biomedical research institute of Nanjing University, Nanjing, China) was also tested. PRVΔTK&gE-AH02, PRV LA-A and parental PRV AH02LA were separately used to inoculate mice subcutaneously with doses of $10^{6.0}, 10^{5.0}, 10^{4.0}$ and $10^{3.0}$ TCID$_{50}$ respectively (Table 2). LD$_{50}$ of each strain for mice were determined following Reed-Muench method. The euthanasia of survived mice were performed using compressed CO$_2$ gas.

**Test of vaccine efficacy of PRVΔTK&gE-AH02**

Twenty four 28~35-day-old piglets (from Zhengzhuquan Pig Breeding Farm in Pukou district, Nanjing, China) were randomly divided into 6 groups (A-F). All piglets were antibody negative for PRV gB and gE, and free of PRRSV, PPV, PCV2 and CSFV. Piglets in group A, B and C were vaccinated with PRVΔTK&gE-AH02 strain with $1 \times 10^{3.0}, 1 \times 10^{4.0}$ and $1 \times 10^{5.0}$ TCID$_{50}$/dose respectively, group D piglets with live Bartha K61 of $1 \times 10^{5.0}$ TCID$_{50}$/dose, and groups E and F piglets were dosed with PBS only (Table 3). All inoculations were given intramuscularly (I.M.) at 2 mL/pig. At 1 week post vaccination (P.V.), groups A, B, C, D and E were challenged intranasally (I.N.) with 2LD$_{50}$ PRV AH02LA per piglet. Group F piglets were not challenged, serving as a negative control. Clinical signs, body temperature and virus shedding were monitored and recorded daily from vaccination to 14 days P.C.. Serum samples from all piglets were collected for PRV gB and gE antibodies test before vaccination, and at 7 days post vaccination (P.V.), and 14 days post challenge (P.C.). All survived piglets were euthanized by injection of pentobarbital. The presence of lung lesions for survived or died piglets was noted at the end of the test.

**Test for serological antibodies**

ELISA tests were performed using PRV gE or gB antibody detection kit (IDEXX, Maine, USA) following the manufacturer's instructions. In safety experiment, all 1-day-old piglets were tested for serum antibodies against PRV gB and gE, and then divided into PRV negative group or positive group accordingly. At 14 days post vaccination, serum samples of all piglets were collected for test of PRV gB and gE antibodies again. In efficacy experiment, serum samples of all piglets were collected before vaccination, at 7 days post vaccination (before challenge) and at 14 days P.C. for test of PRV gB and gE antibodies.

**Detection of virus shedding**

Nasal swab samples were collected daily from all piglets in efficacy experiment from inoculation of vaccines to

### Table 3: Group division and results of antibodies, clinical signs and lung lesions in efficacy test

| Groups | A | B | C | D | E | F |
|--------|---|---|---|---|---|---|
| Virus tested | PRVΔTK&gE-AH02 | Bartha K61 | / | / |
| Dosage (TCID$_{50}$) | $10^{3}$ | $10^{4}$ | $10^{5}$ | $10^{5}$ | / | / |
| Inoculation route | Intramuscularly | / | / | / | / | / |
| ELISA antibodies against PRV gB or gE | B.V. | gB+ | 0/4^a | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| | gE+ | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| 7d P.V. | gB+ | 4/4 | 4/4 | 4/4 | 4/4 | 0/4 | 0/4 |
| | gE+ | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| 14 d P.C. | gB+ | 4/4 | 4/4 | 4/4 | 4/4 | 0/4 | 0/4 |
| | gE+ | 4/4 | 4/4 | 4/4 | 4/4 | 1/1 | 0/4 |
| Clinical signs P.V. | / | / | / | / | / | / |
| Fever frequency (≥40.5 °C) P.V. | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| Virus shedding P.V. | 0/4 | 0/4 | 0/4 | 0/4 | / | / |
| Fever frequency (≥40.5 °C) P.C. | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| Clinical signs P.C. | Morbidity | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| | Duration (days) | / | / | / | / | / | / |
| | Mortality | 0/4 | 0/4 | 0/4 | 0/4 | 3/4 | 0/4 |
| Virus shedding P.C. | Frequency | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| | Duration (days) | / | / | / | / | 3~5 | 2~9 |
| Lung lesions | 0/4 | 0/4 | 0/4 | 0/4 | 2/4 | 4/4 | 0/4 |

*B.V.* means before vaccination, *P.V.* means post vaccination, *P.C.* means post challenge, *gB+* means antibodies against PRV gB positive, *gE+* means antibodies against PRV gE positive, $^a$ indicates the number of piglets positive; $^b$ indicates the number of piglets in the group.
14 days P.C.. Treatment and titration of nasal swab samples were performed following the method as described earlier. Viral DNA isolated from titration cells with typical cytopathogenic effects (CPE) was used as template to amplify a specific fragment of 813 bp in gD gene with a pair of primers (PRV gD part F/R) (Table 1).

Experiments involving virulent PRV were conducted under Biosafety Level 2+ containment. All animal tests were approved by the Experimental Animal Committee of the Jiangsu Academy of Agriculture Sciences and were conducted in accordance with the “Guidelines for Experimental Animals” of the Ministry of Science and Technology (Beijing, China). All animals were fed with complete formula feed and free access to drinking water.

Results

Generation of mutant PRV BAC with TK deletion
Based on BAC PRV-G, we targeted a 347 bp fragment in TK gene. With a first Red recombination, 120 ng of gel-purified DNA of PCR product was electroporated into BAC PRV-G. The PCR product was amplified with a pair of primers (PRV ΔTK check F/R) that specified the homologous sequences to allow recombination. As a result the sequences from position 184 to 530 of TK gene was replaced with a kanamycin resistance cassette. Several colonies with resistance to chloramphenicol and kanamycin were obtained and verified through PCR with a pair of primers (PRV ΔTK check F/R) (data not shown) and through RFLP after digestion with Kpn I (Fig. 2), which showed a band of 5975 bp missed and an additional band of 6639 bp present after the first recombination. One of the verified clones, named BAC PRV ΔTK/gE/gI&K+, was selected to perform the 2nd Red recombination for removal of the kanamycin resistance cassette. Colonies with resistance to chloramphenicol, but sensitive to kanamycin were selected and one of them, named BAC PRV ΔTK/gE/gI, was successfully confirmed through PCR with a pair of primers (PRV ΔTK check F/R) (data not shown) and through RFLP after digestion with Kpn I (Fig. 2), which showed a

![Fig. 2](image-url)
missing band of 6639 bp and instead an additional 5628 bp band present. Finally, the sequencing of the resulting PCR products after removal of kanamycin resistance cassette confirmed the successful deletion of a fragment from position 184 to 530 of TK gene in the genome of BAC PRV-G.

Reconstitution of a TK&gE dual deletion PRV from cloned DNA
After co-transfection of BAC \( \text{PRV}^\Delta \text{TK/gE/gI} \) DNA with a DNA fragment that was amplified with primers PRV BAC H1 F and PRV BAC H2 F R (Table 1) using PRV LA-AB DNA as template, non-fluorescing plaques were observed under UV illumination at 488 nm (Fig. 3). The recombinant virus was purified after several rounds of picking and plating, and designated PRV\(^\Delta\text{TK&gE-AH02}\). The deletion of TK and gE and the recovery of gI were verified by PCR using primers of PRV \(^\Delta\text{TK check F/R}\) and PRV \(^\Delta\text{gE check F/R}\) respectively (Table 1). Sequencing with appropriate primers revealed the correct deletion of the 347 bp fragment in TK gene and the deletion of the 1286 bp fragment(position 13 to 1298) in gE gene and successful recovery of gI gene.

Growth kinetics of the PRV\(^\Delta\text{TK&gE-AH02}\) virus
Multistep growth kinetics for the PRV AH02LA, LA-A\(^B\), and PRV\(^\Delta\text{TK&gE-AH02}\) viruses were determined on ST cells and the differences of titers at 48 h P.I. were statistically analyzed. For supernatant virus, peak titers for AH02LA, LA-A\(^B\), and PRV\(^\Delta\text{TK&gE-AH02}\) were \(10^{8.81}\), \(10^{8.71}\), and \(10^{8.19}\) TCID\(_{50}\)/mL respectively. At 48 hpi the titers of PRV\(^\Delta\text{TK&gE-AH02}\) were not significantly different from LA-A\(^B\) (\(p = 0.212\)), while significantly different from AH02LA (\(p = 0.042\)). For cell- associated virus, peak titers for AH02LA, LA-A\(^B\), and PRV\(^\Delta\text{TK&gE-AH02}\) were \(10^{8.71}\), \(10^{8.49}\), and \(10^{7.81}\) TCID\(_{50}\)/mL respectively. At 48 hpi the titers of PRV\(^\Delta\text{TK&gE-AH02}\) were significantly different from LA-A\(^B\) (\(p = 0.016\), and AH02LA (\(p = 0.001\)). The results indicate that even though the mutant virus PRV\(^\Delta\text{TK&gE-AH02}\) can not propagate on ST cells as efficiently as LA-A\(^B\) or AH02LA strain after deletion of TK gene, it reaches titers of more than \(10^{8.00}\) TCID\(_{50}\)/mL (Fig. 4).

Safety of the PRV\(^\Delta\text{TK&gE-AH02}\) vaccine
For 1-day-old PRV antibody negative piglets, 2 of 4 piglets in group A(N) showed typical clinical signs of PR from 3 days after inoculation intranasally with PRV\(^\Delta\text{TK&gE-AH02}\), and one of the two ill piglets died at 7 days P.I. All the 4 piglets in group B(N) showed typical clinical signs of PR from 2 to 3 days after intranasal vaccination with PRV LA-A\(^B\) and all died at 3 to 5 days P.I. In groups C(N) and D(N), 1 out of 4 and 4 out of 4 showed PR signs from 3 to 4 days post vaccination intramuscularly with PRV PRV\(^\Delta\text{TK&gE-AH02}\) or LA-A\(^B\). No animal died in group C(N),while 3 out of 4 died in group D(N) at 4 to 7 days P.I.. No PRV gE antibodies was detected in all survived piglets. All animals in placebo control group(E(N)) were healthy during the whole test(Table 2)(Fig. 5).

For 1-day-old PRV antibody positive piglets, neither PRV\(^\Delta\text{TK&gE-AH02}\) (group A(P) and C(P)) nor LA-A\(^B\) (group B(P) and D(P)) showed any virulence post inoculation either intranasally or intramuscularly(Fig. 5). No PRV gE antibody was detected in all animals at 14d P.I. (Table 2). The virulence to mice was reduced after deletion of gE gene and attenuated further after TK&gE dual deletion. LD\(_{50}\) to mice of AH02LA was \(10^{3.66}\) TCID\(_{50}\), and went up to \(10^{5.29}\) TCID\(_{50}\) for LA-A\(^B\) strain, while PRV\(^\Delta\text{TK&gE-AH02}\) did show virulence to mice at a dose of \(10^{6.00}\) TCID\(_{50}\).

Immunogenicity of the PRV\(^\Delta\text{TK&gE-AH02}\) vaccine
In group E (challenge control), all piglets showed clinical signs of pseudorabies infection including sneezing, coughing, nasal discharge, respiratory distress, lack of coordination, circling and paralysis from 2 days to 11 days P.C.. One piglet died at 8 days and two at 10 days P.C. (Table 3) (Fig. 5). Body temperatures of all these
piglets reached over 40.5 °C and lasted for 4~10 days (data not shown). All piglets shed virus from 2 or 3 days P.C. and lasting for 5~7 days till death or 6~10 days for the surviving piglets. PCR using primers((PRV gD part F/R)(Table 1)) with the DNA of isolated virus as template amplified a specific fragment of 813 bp as suspected (data not shown). All piglets showed severe lung lesions from hemorrhaging and congestion (Table 3). All animals in group F (placebo control) were healthy during the whole test (Table 3).

At 7 days post vaccination (P.V.), gB antibodies in all piglets vaccinated with the PRVΔTK&gE-AH02 strain or Bartha K61 strain were detected positive. All piglets in vaccination groups A, B, C and D or survived piglets in group E were positive for gE antibodies at 14 days P.C. (Table 3). All animals in group F (placebo control) were gE and gB negative during the whole test (Table 3).

All piglets in the vaccinated groups (A, B, C and D) were protected against lethal challenge (Fig. 5). No fever, virus shedding or other clinical symptoms were observed in group A, B and C vaccinated with PRVΔTK&gE-AH02 strain. While all four piglets in group D vaccinated with Bartha K61 strain showed fevers of ≥40.5 °C and virus shedding was detected for 3~5 days, even though no other clinical signs were observed in this group (Table 3). Special fragments of 813 bp were amplified through PCR with DNA of isolated virus as template and with primers (PRV gD part F/R). No lung lesions were observed in piglets of groups A, B or C at 14 days P.C., while 2 out of 4 piglets in group D and all group E piglets presented lesions from hemorrhage and/or congestion after death or euthanization at 14 days P.C. (Table 3).

**Discussion**

Owing to the implementation of DIVA based vaccine [9], PRV eradication has been achieved with remarkable success [6]. Some developed countries including USA and several European nations have declared PRV free in domestic swine populations. In China, PRV was well controlled through intensive vaccination of traditional vaccines including Bartha K61 until late 2011, when a novel PRV variant with enhanced virulence emerged in several pig herds [2, 3]. AH02LA strain was isolated from the brain of a dead 1-day-old piglet in a pig farm during a PR outbreak in Anhui province of China in 2012 [23]. Sequence analysis reveals that AH02LA strain belongs to the same clade as the other new PRV variants isolated after 2011 in China [23, 28], and has significant mutations in gB, gD and gC genes when compared to the most popular vaccine strain Bartha K61 strain. Specially, gB (GenBank: KR605319) of AH02LA contains a 4 amino acid (aa)
deletion at positions 75 to 78, a 4 aa insertion at positions 121 to 124, and 33 non-synonymous substitutions. The gC gene (GenBank: KR605320) of AH02LA contains a 2 nucleotide insertion at position 176 and 177, a 7 nucleotides insertions at position 184 to 190 and a 12 nucleotide insertion at position 196 to 207, leading to a 7 aa insertion, several aa changes, and 35 non-synonymous substitutions. The gD (GenBank: KR605321) of AH02LA contains a 2 aa insertion at positions 275 and 276 and 9 non-synonymous substitutions. gD, gB and gC are the major neutralizing stimulation antigens of PRV, the reduced protection efficiency of Bartha K61 vaccines against AH02LA strain might be closely associated with the mutations in these three genes. Theoretically, gene deletion mutants from homologous virulent virus could provide better protection.

To avoid the potential threat of the latent infection of PRV to porcine herds, the eradication strategy has been a direct selection of many countries or pig farms. DIVA vaccines have played an important role for control of disease and efficient reduction of virus shedding post infection with virulent strain. For differentiation purpose, gE deletion is the normal choice and the absence of gE can reduce the virulence of virus without affecting its immunogenicity and growth ability [29, 30]. However, absence of gE along can not be used as a live vaccine without further attenuation by an additional deletion of TK gene. In this study, a live vaccine candidate of TK&gE dual deletion strain (PRVΔTK&gE-AH02 strain) from the emerging PRV AH02LA strain was constructed successfully. Safety and efficacy tests demonstrated significant attenuation of the PRVΔTK&gE-AH02 strain virus and complete protection at 7 only days post vaccination. The PRVΔTK&gE-AH02 strain had stopped virus shedding against challenge by virulent AH02LA strain, suggesting that it is superior to the Bartha K61 strain for the eradication of virulent virus. It is worth noting that the PRVΔTK&gE-AH02 strain exhibited impaired replication in ST cells due to the deletion of TK and reached significantly reduced titers when compared to AH02LA or LA-A strain. Nevertheless, the peak titer of PRVΔTK&gE-AH02 strain still reached 10^8.0 TCID_{50} /mL which is sufficient for the production of a live vaccine.

---

**Fig. 5** Safety and efficiency of TK&gE dual deletion mutant virus for piglets: 

- **a** Safety for 1-day-old PRV gB antibody negative piglets were tested.
- **b** Safety for 1-day-old PRV gB antibody positive piglets were tested.
- **c** A total of 24 28–35-day-old PRV gB antibody negative piglets were randomly divided into six groups of A-F. One week post vaccination, groups A, B, C, D and E were challenged intranasally with 2LD_{50} PRV AH02LA per piglet. Group F piglets were not challenged. The survival rates of these groups over the 14 days post challenge are shown. I.N.: intranasally; I.M.: intramuscularly.
In practice, 1-day-old piglets are inoculated intranasally (LN) with live vaccine in porcine farms that suffered from PRV emerging variants infection or under the threat of the infection. The safety test of PRVΔTK&gE-AH02 strain for 1-day-old piglets demonstrated that both PRVΔTK&gE-AH02 strain and LA-A strain are safe for PRV antibody positive piglets. However, although PRVΔTK&gE-AH02 strain showed less virulence than LA-A strain in piglets without PRV antibody, it caused lethal infection after inoculation LN or IM. These results indicate that further attenuation might be necessary to improve the safety of PRVΔTK&gE-AH02. However, since farm pig herds are PRV antibody positive due to intensive vaccination of PRV vaccine and newborn piglets are surely PRV antibody positive after intake of sow’s colostrum, indicating that the PRVΔTK&gE-AH02 strain should be safe for 1-day-old inoculation in farm pig herds.

Bacterial artificial chromosome (BAC) of PRV is a useful tool for the study of the virus [31–33]. After the construction of the first PRV BAC of Becker strain, a few of other PRV genomes have been maintained in BACs as infectious clones [14, 34, 35]. The infectious clone of the PRV AH02LA strain (BAC-PRV-G) was previously constructed in our lab and was used in this study to generate the TK deletion BAC mutant by En Passant protocol. Additionally, this BAC can be used for the mechanistic analysis of the high virulence of this variant and the construction of other viral vectored vaccines.

Conclusion
A TK&gE dual deletion mutant (PRVΔTK&gE-AH02 strain) was generated successfully based on the BAC of the virulent PRV AH02LA strain. The PRVΔTK&gE-AH02 strain was highly attenuated for 1-day-old piglets or mice. Live vaccine made of PRVΔTK&gE-AH02 strain is safe for 4–5 week-old PRV antibody negative piglets and can provide complete protection against lethal challenge with the emerging PRV virulent strain AH02LA at only 7 days post vaccination. Most importantly, PRVΔTK&gE-AH02 can stop virus shedding post lethal challenge and thus might be a promising vaccine candidate for the eradication of emerging virulent mutants of PRV in China.

Abbreviations
aa: Amino acid; BAC: Bacterial artificial chromosome; CEC: Chicken embryo cell; CPE: Cytopathogenic effects; CSF: Classical swine fever virus; DNA: Deoxyribonucleic acid; ELISA: Enzyme-linked immunosorbent assay; gB: Glycoprotein B; gC: Glycoprotein C; gD: Glycoprotein D; gE: Glycoprotein E; gG: Glycoprotein G; gI: Glycoprotein I; IM: Intramuscularly; IN: Intranasally; LD<sub>50</sub>: 50% lethal dose; MOL: Multiplicity of infection; P.C.: Post challenge; P.I.: Post infection; P.V.: Post vaccination; PCR: Polymerase chain reaction; PCV2: Porcine circovirus 2; PPV: Porcine parvovirus; PRRSV: Porcine reproductive and respiratory syndrome virus; PRV: Pseudorabies virus; RFLP: Restriction fragment length polymorphism; TCID<sub>50</sub>: 50% tissue culture infectious dose; TK: Thymidine kinase; UV: Ultraviolet

Acknowledgements
We thanks professor Nikolaus Osterrieder at the Free University of Berlin for kindly providing E.coli GS1783.

Funding
This study was supported by the Special Fund for Agro-Scientific Research in the Public Interest (201303046), Program for Independence and Innovation in Agricultural Sciences of Jiangsu Province (CX(12)3061 and CX(14)2084), and the Natural Science Foundation of Jiangsu Province (BK20131334).

Availability of data and materials
The PRV AH02LA strain and Other materials or datasets used or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
JW HF and JH designed the generation TK&gE dual deletion mutant. JW, YQ, ZW and AG contributed to the design and performance of animal tests. JW, ZS and RG constructed the TK deleted PRV BAC and the TK&gE deleted virus. ZS, AG, YQ, MX, ZW, YL and YZ investigated the related properties of the vaccine and performed the animal experiments and related tests. All authors read and approved the final manuscript.

Ethics approval
All animal tests were approved by the Experimental Animal Committee of the Jiangsu Academy of Agriculture Sciences and were conducted in accordance with the “Guidelines for Experimental Animals” of the Ministry of Science and Technology (Beijing, China). Experiments involving virulent PRV were conducted under Biosafety Level 2+ containment.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflicts of interest.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1National Research Center of Engineering and Technology for Veterinary Biologicals/Institute of Veterinary Immunology & Engineering, Jiangsu Academy of Agricultural Sciences, Nanjing 210014, Jiangsu, China. 2Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, China. 3College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China. 4Shandong Vocational Animal Science and Veterinary College, Weifang 261061, China. 5Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Nanjing 210014, Jiangsu, China.

Received: 14 August 2017 Accepted: 19 June 2018
Published online: 21 September 2018

References
1. An T, Peng J, Tian Z, Zhao H, Li N, Liu Y, et al. Pseudorabies virus variant in bartha-k61-vaccinated pigs, China, 2012. Emerg Infect Dis. 2013;19(11):1749–55.
2. Wu R, Bai C, Sun L, Chang S, Zhang X. Emergence of virulent pseudorabies virus infection in northern China. J Vet Sci. 2013;14(3):363–5.
3. Yu X, Zhou H, Hu D, Zhang Q, Han T, Li X, et al. Pathogenic pseudorabies virus, China, 2012. Emerg Infect Dis. 2014(20):102–4.
4. Hu D, Zhang Z, Lv L, Xiao Y, Qi Y, Ma H, et al. Outbreak of variant pseudorabies virus in Bartha-K61-vaccinated piglets in Central Shandong Province, China. J Vet Diagn Invest. 2015;27:600–5.
5. Zhou J, Li S, Wang X, Zou M, Gao S. Bartha-k61 vaccine protects growing pigs against challenge with an emerging variant pseudorabies virus. Vaccine. 2017;35:1161–6.
6. Freuling CM, Müller TF, Mettenleiter TC. Vaccines against pseudorabies virus (PrV). Vet Microbiol. 2017;206:3–9.
7. Müller T, Hahn E, Tottewitz F, Kaminer M, Klupp B, Mettenleiter T, et al. Pseudorabies virus in wild swine: a global perspective. Arch Virol. 2011;156(10):1691–705.
8. Lyman M, Demmin G, Banfield B. The attenuated pseudorabies virus strain Bartha fails to package the tegument proteins Us3 and VP22. J Virol. 2003;77(2):1403–14.
